Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Transforming growth factor-beta-1

Drug Profile

Transforming growth factor-beta-1

Alternative Names: TGF-beta-1; Transforming growth factor-beta

Latest Information Update: 14 Nov 2006

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Genentech; National Cancer Institute (USA)
  • Class Antineoplastics; Antivirals; Growth factors; Nootropics; Transforming growth factors
  • Mechanism of Action Transforming growth factor beta1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Atherosclerosis; Cancer; Skin disorders; Systemic lupus erythematosus

Most Recent Events

  • 17 Sep 2001 A study has been added to the Alzheimer's Disease pharmacodynamics section
  • 14 Jan 1997 Preclinical development for Skin disorders in USA (Unknown route)
  • 04 Dec 1996 Preclinical development for Systemic lupus erythematosus (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top